Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIB, Open Label, Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies, Scheduled to Receive Immunotherapy (IOT) as a Single Agent or Combination, to Predict Response to Therapy

NCT05013099 is registered in ClinicalTrials.gov with ImaginAb, Inc. as lead sponsor.

NCT NCT05013099
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05013099 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIB, Open Label, Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies, Scheduled to Receive Immunotherapy (IOT) as a Single Agent or Combination, to Predict Response to Therapy
Lead sponsor
ImaginAb, Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
December 9, 2021
Completion date
July 31, 2025
Enrollment
70 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, merkel cell carcinoma, unspecified, non small cell lung cancer, renal cell carcinoma